PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
405203 100 µg £35
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405204 500 µg £121
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified

Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References

(PubMed link indicates BioLegend citation)
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  2. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  3. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  4. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  5. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  6. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  7. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  8. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  9. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  10. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  11. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  12. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  13. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  14. He X, et al. 2014. J Immunol. 193:1314. PubMed
  15. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  16. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  17. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  18. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  19. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  20. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  21. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  22. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  23. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  24. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  25. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  26. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  27. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  28. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  29. Im S, et al. 2016. Nature. 537:417-421. PubMed
  30. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  31. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  32. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  33. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  34. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  35. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  36. Köchl R, et al. 2020. Elife. 9:00. PubMed
  37. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  38. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  39. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  40. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  41. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  42. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  43. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  44. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  45. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  46. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed
  47. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  48. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  49. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  50. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  51. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  52. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  53. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  54. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  55. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  56. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  57. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  58. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  59. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  60. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  61. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  62. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  63. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  64. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  65. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  66. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  67. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  68. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  69. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  70. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  71. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  72. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  73. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  74. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  75. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06/17/2019

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account